Zimmer Partners LP Purchases New Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Zimmer Partners LP purchased a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 1st quarter, HoldingsChannel.com reports. The firm purchased 721,700 shares of the company’s stock, valued at approximately $11,093,000.

Several other institutional investors also recently added to or reduced their stakes in TEVA. Ameriprise Financial Inc. grew its position in Teva Pharmaceutical Industries by 3.9% during the fourth quarter. Ameriprise Financial Inc. now owns 147,649 shares of the company’s stock valued at $3,254,000 after buying an additional 5,494 shares during the period. Ethic Inc. lifted its holdings in Teva Pharmaceutical Industries by 45.4% during the fourth quarter. Ethic Inc. now owns 55,323 shares of the company’s stock valued at $1,219,000 after purchasing an additional 17,267 shares during the last quarter. Focus Partners Wealth lifted its holdings in Teva Pharmaceutical Industries by 8.7% during the fourth quarter. Focus Partners Wealth now owns 38,335 shares of the company’s stock valued at $845,000 after purchasing an additional 3,071 shares during the last quarter. Graham Capital Management L.P. lifted its holdings in Teva Pharmaceutical Industries by 148.4% during the fourth quarter. Graham Capital Management L.P. now owns 76,232 shares of the company’s stock valued at $1,680,000 after purchasing an additional 45,542 shares during the last quarter. Finally, Jefferies Financial Group Inc. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $332,000. Institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Placid Jover sold 6,053 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Trading Up 1.8%

Shares of Teva Pharmaceutical Industries stock opened at $19.30 on Tuesday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a market cap of $22.13 billion, a price-to-earnings ratio of -120.61, a PEG ratio of 1.12 and a beta of 0.72. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The company’s 50-day moving average price is $17.09 and its 200-day moving average price is $16.41.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same period in the prior year, the firm posted $0.61 earnings per share. The company’s revenue for the quarter was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the topic of several recent research reports. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $21.00 to $23.00 in a report on Monday, May 12th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a “buy” rating and a $24.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.